Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma

Cancer Science

Volumn 99, Issue 1, 2008, Pages 140-144

  Ogawa, Yoshiaki ^a,d   Tobinai, Kensei ^b   Ogura, Michinori ^c   Ando, Kiyoshi ^a   Tsuchiya, Takahide ^a   Kobayashi, Yukio ^b   Watanabe, Takashi ^b   Maruyama, Dai ^b   Morishima, Yasuo ^c   Kagami, Yoshitoyo ^c   Taji, Hirofumi ^c   Minami, Hironobu ^d   Itoh, Kuniaki ^d   Nakata, Masanobu ^d   Hotta, Tomomitsu ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BORTEZOMIB; INTERFERON; OXYGEN; PROTEASOME INHIBITOR; STEROID; THALIDOMIDE; VINCA ALKALOID;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER RELAPSE; CANCER RESISTANCE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; INTERSTITIAL LUNG DISEASE; JAPANESE; KIDNEY DISEASE; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; THROMBOCYTOPENIA; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROTEASE INHIBITORS; PYRAZINES;

EID: 36949037803     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00638.x     Document Type: Article

References (16)

1. Oken MM. Standard treatment of multiple myeloma. Mayo Clin Proc 1994; 69: 781-6.
2. Oken MM. Management of myeloma: Current and future approaches. Cancer Control 1998; 5: 218-25.
3. Paccagnella A, Chiarion-Sileni V, Soesan M et al. Second and third responses to the same induction regimen in relapsing patients with multiple myeloma. Cancer 1991; 68: 975-80.
4. Attal M, Harousseau J, Stoppa J et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Eng J Med 1996; 335: 91-7.
5. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-83.
6. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353-6.
7. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986; 105: 8-11.
8. Buzaid AC, Durie BG. Management of refractory myeloma: A review. J Clin Oncol 1988; 6: 889-905.
9. Appleman LJ, Ryan DP, Clark JW et al. Phase 1 dose escalation study of bortezomib and gemcitabine safety and tolerability in patients with advanced solid tumors. 39th Annual Meeting of the American Society of Clinical Oncology 2003 (abstract 839).
10. Papandreou CN, Daliani DD, Nix D et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2108-21.
11. Huang Y, Hamilton A, Arnuk OJ, Chaftari P, Chemaly R. Current drug therapy for multiple myeloma. Drugs 1999; 57: 485-506.
12. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood Marrow Transplant Br J Haematol 1998; 102: 1115-23.
13. Nix DJ, Pien C, LaButti J et al. Clinical pharmacology of the proteasome inhibitor PS-341. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2001 (abstract 389).
14. Lightcap ES, McCormack TA, Pien CS et al. Proteasome inhibition measurements: Clinical application. Clin Chem 2000; 46: 673-83.
15. Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-17.
16. Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-98.